Results 1 to 10 of about 1,268 (176)

Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase [PDF]

Frontiers in Immunology
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are autoimmune antibody-mediated diseases.
Weifan Yin, Weifan Yin, Shige Wang, Wei Lu, Wei Lu, Tianjiao Duan, Tianjiao Duan   +6 more
doaj   +2 more sources

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study [PDF]

Frontiers in Immunology
ObjectiveTo analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical ...
Yutong Wu, Yue Zhou, Wanshuang Yin, Xiao Zhao, Lingxu Xu, Yinchao Su, Shuxin Wang, Siyu Li, Yue Wang, Chunmei Duan, Yiliang Fang, Zhaoyou Meng   +11 more
doaj   +2 more sources

Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial [PDF]

Frontiers in Immunology
Background/objectiveEfgartigimod, a human immunoglobulin G1 (IgG1) antibody Fc fragment, reduces IgG levels through neonatal Fc receptor (FcRn) blockade.
Antoine E. Azar, John W. Sleasman, Sophie Steeland, Fien M. Verhamme, Kevin L. Winthrop   +4 more
doaj   +2 more sources

Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis

Scientific Reports
Impending myasthenic crisis (IMC) is an emergent situation requiring aggressive management to prevent patients from developing myasthenic crisis (MC) in patients with myasthenia gravis (MG).
Pang Xiaomin, Duan Weisong, Chang Xueli   +2 more
exaly   +2 more sources

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial [PDF]

Therapeutic Advances in Neurological Disorders
Summary What is this summary about? This is a plain language summary of an article published in The Lancet Neurology in 2024. The article describes the results of the ADHERE clinical study, which involved people with chronic inflammatory demyelinating ...
Jeffrey A. Allen, Luis Querol, Niraja Suresh, Anneleen Remmerie, Trevor Mole, Kelly McCoy, Lisa Butler, Benjamin van Hoorick, Satoshi Kuwabara, Pieter A. van Doorn, Richard A. Lewis   +10 more
doaj   +2 more sources

Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan [PDF]

Frontiers in Neurology
BackgroundEfgartigimod, a neonatal Fc receptor blocker, has received regulatory approval for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Japan in December 2024.AimsTo investigate the effectiveness and safety of ...
Tatsuya Imai, Kenichi Irie, Shinichiro Mori, Tomoaki Hoshino, Toshihiro Ide, Takahisa Tateishi   +5 more
doaj   +2 more sources

Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy [PDF]

Frontiers in Immunology
BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated polyneuropathy. Early and effective immunomodulatory treatment is essential to prevent long-term disability.
Yanping Ran, Wenlin Wu, Chi Hou, Haixia Zhu, Wenxiao Wu, Zongzong Chen, Xuexia Ma, Xiaolan Mo, Houliang Deng, Yuanyuan Gao, Xiaojing Li   +10 more
doaj   +2 more sources

Add-on efgartigimod in myasthenic crisis: a promising treatment option [PDF]

Frontiers in Neurology
BackgroundIn myasthenia crisis (MC), plasma exchange (PE) and intravenous immunoglobulin (IVIG) are confirmed effective treatment options, but PE may not be available in time, and the response rate to IVIG is not always satisfactory.
Fangyi Shi, Fangyi Shi, Fangyi Shi, Jing Wang, Jing Wang, Jing Wang, Jiaxin Chen, Jiaxin Chen, Jiaxin Chen, Rong Lai, Rong Lai, Rong Lai, Li Feng, Li Feng, Li Feng, Hongyan Zhou, Hongyan Zhou, Hongyan Zhou, Xunsha Sun, Xunsha Sun, Xunsha Sun, Cunzhou Shen, Cunzhou Shen, Cunzhou Shen, Jiezhen Feng, Jiezhen Feng, Jiezhen Feng, Xin Huang, Xin Huang, Xin Huang, Huiyu Feng, Huiyu Feng, Huiyu Feng, Haiyan Wang, Haiyan Wang, Haiyan Wang   +35 more
doaj   +2 more sources

Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod [PDF]

Scientific Reports
Efgartigimod, a neonatal Fc receptor inhibitor that accelerates IgG degradation, remains understudied in treatment of Guillain-Barré Syndrome (GBS). This study aimed to evaluate the efficacy and safety of efgartigimod in GBS patients.
Yifan Cheng, Wenyu Li, Siyu Xie, Shunyuan Guo, Chunrong Li, Manman Zhang, Yiqi Wang   +6 more
doaj   +2 more sources

Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report [PDF]

Frontiers in Immunology
BackgroundWhile immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, neurological immune-related adverse events (n-irAEs) associated with these agents are increasingly recognized. However, kelch-like protein-11(KLHL11)-IgG cerebellitis
Yi-Xiao Li, Zhong-Mian Ma
doaj   +2 more sources